What's Going On With Caribou Biosciences Shares Today?

Caribou Biosciences, Inc. CRBU shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology Association 2022 Hybrid Congress.

A 100% complete response rate (6 of 6 patients) was observed as best response, with a 40% complete response rate (2 of 5 patients) at 6 months.

Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer said, “We believe the 100% complete response achieved in the ANTLER CB-010 trial is unparalleled for a single, starting dose of cell therapy and represents an important step toward showing the potential of our chRDNA genome-editing platform and pipeline of allogeneic cell therapies.”

Caribou Biosciences Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

The stock was trading about 33% lower at $5.79 per share on Friday at the time of publication.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Small CapMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!